Allyson Masci joined Peptimmune in 2006 as a summer intern working in the pharmacology/immunology group. Allyson is completing her BS at a local university.
7/30/2008 – Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the…
7/16/2008 – Peptimmune announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New…
6/17/2008 – Peptimmune announces first patient dosed in a phase Ib study of PI-2301 in multiple sclerosis patients in one of the most comprehensive studies of the…